IGC Pharma Inc (NYSE American: IGC), a clinical-stage pharmaceutical company, announced on Tuesday that it has received a Granting Office Action (GOA) from the Divisional Direction of Patents, Mexico, for its Alzheimer's disease treatment titled 'Method and Composition for Treating CNS Disorder'. This patent success in Mexico positions IGC Pharma optimistically for additional approvals in the U.S. and Europe.

The patented drug formulation, targeting Central Nervous System (CNS) Disorders, is a significant achievement for IGC Pharma. The company is currently advancing a Phase 2 trial for IGC-AD1, its lead therapeutic candidate designed to address agitation in Alzheimer's disease, the most common form of CNS disorder. IGC-AD1, a partial CB1 receptor agonist, aims to alleviate neuropsychiatric symptoms through anti-neuroinflammatory properties.

With Alzheimer's disease posing a growing global health concern, IGC-AD1 is strategically positioned to revolutionise treatment. The current Phase 2 trial seeks to validate its effectiveness in managing agitation and relieving caregiver burden, potentially improving the quality of life for millions affected by the disease.

IGC Pharma's drug portfolio includes five assets targeting Alzheimer's treatment, including IGC-AD1, TGR-63, LMP, IGC-1C and IGC-M3, all in various stages of clinical trials and development. These assets focus on neuroinflammation, Aβ plaques, neurofibrillary tangles and tau in innovative approaches to Alzheimer's therapy.

In addition to its drug development initiatives, IGC Pharma is at the forefront of Generative AI projects, including clinical trials, early Alzheimer's detection, and exploring drug interactions with cannabinoids.